

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1011)

PROFIT WARNING REDUCTION IN LOSS SUPPLEMENTAL ANNOUNCEMENT

This announcement is made by China NT Pharma Group Company Limited (the "**Company**", and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the profit warning announcement of the Company dated 26 February 2026 (the "**Previous Announcement**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Previous Announcement.

Following further discussions with the Company's auditor (the "**Auditor**") in the course of the audit, and based on the Auditor's audit work completed up to the date of this announcement, the Board wishes to further inform the Shareholders and potential investors that the Group is expected to recognise a one-off non-cash gain of approximately HK\$15.4 million (equivalent to approximately RMB14.1 million) in respect of the issue of new shares for the settlement of debt. Accordingly, the expected loss of the Group for the year ended 31 December 2025 will be further reduced by approximately HK\$15.4 million (equivalent to approximately RMB14.1 million) as compared with that disclosed in the Previous Announcement, and the revised expected net loss will be in the range of approximately RMB10.9 million to RMB15.9 million.

Save as disclosed above, all other information and content set out in the Previous Announcement remain unchanged. This announcement is supplemental to and should be read in conjunction with the Previous Announcement.

The Company has scheduled a board meeting to be held on Tuesday, 31 March 2026 to consider and approve the annual results of the Group for the year ended 31 December 2025 and their publication.

Shareholders and potential investors are advised to read carefully the financial information of the Group in the Group's audited annual results announcement for the Year to be published on 31 March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professional or financial advisers.

By order of the Board

China NT Pharma Group Company Limited

Chairman

NG Tit

Hong Kong, 30 March 2026

As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.